AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02889679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard polypectomy
Description: Standard polypectomy will be performed for diminutive (\<6mm), pedunculated and semi-pedunculated lesions that do not fall under the inclusion criteria for the study. These lesions will be removed in a gas distended colon with a 9mm firm, thin wire cold snare or snare electrocautery for large (≥1cm) lesions.
Study NCT02889679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard polypectomy
Description: Standard polypectomy will be performed for diminutive (\<6mm), pedunculated and semi-pedunculated lesions that do not fall under the inclusion criteria for the study. These lesions will be removed in a gas distended colon with a 9mm firm, thin wire cold snare or snare electrocautery for large (≥1cm) lesions.
Study NCT03625037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Administered as specified in the treatment arm.
Study NCT03833089 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Targeted serum potassium level
Description: In the following order, following advices end prescriptions will be provided: 1) Potassium rich dietary advice, 2) Potassium supplementation, 3) mineralocorticoid receptor antagonists,
Study NCT03198455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agaricus blazei Murill-based mushroom extract, Andosan™
Description: Dietary Supplement: Agaricus blazei Murill-based mushroom extract, Andosan™
Study NCT03198455 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drinking water with food coloring and salt
Study NCT00003136 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00003136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Study NCT00003136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00003136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00003136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT01007071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Growth Hormone (1-134)
Description: Subjects randomized to human growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Women premenopausal or on estrogen: start at 0.6 mg sc/d, increase to 1.3 mg sc/d after 4 weeks.) Dose adjustments based on serum IGF-1 levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 SD to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.
Study NCT01007071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo
Study NCT03423108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: G150
Description: This group will receive 150 min/week of combined exercise training, structured and supervised.
Study NCT03423108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: G300
Description: This group will receive 300 min/week of combined exercise training, structured and supervised.
Study NCT03094078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News item with spin
Description: Interpretation of news item with spin
Study NCT03094078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News item without spin
Description: Interpretation of news item without spin
Study NCT03516227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: heart rate variability biofeedback
Description: The HRVBF group received four, one-on-one bedside biofeedback training sessions (20-minutes a day for 4 days), and practiced on their own (10-minutes twice a day) using a FDA-regulated, hand-held mobile biofeedback device (StressEraser, Helico Inc., New York, NY, USA).26 The control group received usual care.Afterwards, all participants were telephoned bi-weekly and encouraged to practice slow breathing (HRVBF group) or to perform self-care (control group) for three months.
Study NCT02055872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous albumin
Study NCT02055872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT01658137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prudent Diet
Description: This intervention lasts 2 weeks (14 days).
Study NCT01658137 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Typical Western Diet
Description: This intervention lasts 2 weeks (14 days).
Study NCT01011803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined speech therapy tools, measures of swallowing function
Description: All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were \[diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)\]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
Study NCT04031274 — intervention group
Intervention type: DEVICE
Intervention: TAVI
Description: Trascatheter aortic valve implantation
Study NCT02548091 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10)
Description: The same amount of blood sample is collected from both arms of study at the same time of the procedure.~In each patient, in the per procedure period, a total of 50 milliliters of blood sample is drawn from the pulmonary circulation downstream and upstream of obstructive lesion, the trunk of pulmonary artery, the superior vena cava and the femoral arterial line prior to angioplasty and at the end of procedure; in the post interventional care unit 10 milliliters of blood sample will be draw daily from the superior vena cava catheter line and femoral arterial line.
Study NCT02548091 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10)
Description: The same amount of blood sample is collected from both arms of study at the same time of the procedure.~In each patient, in the per procedure period, a total of 50 milliliters of blood sample is drawn from the pulmonary circulation downstream and upstream of obstructive lesion, the trunk of pulmonary artery, the superior vena cava and the femoral arterial line prior to angioplasty and at the end of procedure; in the post interventional care unit 10 milliliters of blood sample will be draw daily from the superior vena cava catheter line and femoral arterial line.
Study NCT02548091 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non invasive ventilation
Study NCT03600974 — intervention group
Intervention type: PROCEDURE
Intervention: Stretta
Description: Stretta for Endoscopy-E(+),Acid-A(+),Reflux-symptom association-S(+) or lower oesophageal sphincter-L(+) group
Study NCT02548091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation
Study NCT02548091 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: monitoring system Pulse-Induced Contour Cardiac Output (Picco)
Study NCT02548091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: monitoring system Pulse-Induced Contour Cardiac Output (Picco)
Study NCT04031274 — intervention group
Intervention type: DEVICE
Intervention: TMVR/r
Description: Transcatheter mitral valve replacement/repair
Study NCT03221790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low FODMAP Diet followed by a High FODMAP Diet
Description: 3 weeks on a low FODMAP diet followed by 3 weeks on a high FODMAP Diet
Study NCT01549535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system
Description: endoscopic diagnosis, treatment and video observation of the digestive tract, endoscopy and endoscopic treatment within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) of adults patients
Study NCT03734978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: biochemistry
Study NCT01691677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days
Study NCT03600974 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Nissen fundoplication
Description: Laparoscopic Nissen fundoplication for E(+),A(+) or L(+) group
Study NCT01691677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days
Study NCT01778374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No participant choice of counselor
Description: Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
Study NCT01778374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participant choice of counselor
Description: Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
Study NCT04405544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT-scan
Description: chest CT-scan
Study NCT04405544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EEG
Description: Electroencephalography
Study NCT04405544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EP
Description: Evoked potential
Study NCT04405544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pulse oximetry
Description: Pulse oximetry
Study NCT04405544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood tests
Description: Blood tests
Study NCT04422561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Tablets
Description: two doses 72 hours apart
Study NCT03600974 — intervention group
Intervention type: DRUG
Intervention: Probiotic Agent
Description: Probiotic Agent for I(+)G/W；Live Bacillus Licheniformis Cranules 0.5g bid； Bifidbacterium 0.63g bid
Study NCT03600974 — intervention group
Intervention type: DRUG
Intervention: PPI
Description: PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid；omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid
Study NCT03600974 — intervention group
Intervention type: DRUG
Intervention: Prokinetic Motility Agents
Description: Prokinetic Motility Agents for M(+) group; Mosapride 5mg Tid; Domperidone 10mg Tid
Study NCT00336791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: FEC Chemotherapy: 500 mg/m\^2 IV on day 1 of 21 day cycle.~FAC Chemotherapy: 500 mg/m\^2 IV on day 1 and day 4 of 21 day cycle.
Study NCT00336791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: FEC Chemotherapy: 500 mg/m\^2 IV on day 1 of 21 day cycle.~FAC Chemotherapy: 500 mg/m\^2 IV on day 1 and day 4 of 21 day cycle.
Study NCT00336791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: FAC and FEC Chemotherapy:~500 mg/m\^2 IV on day 1 of 21 day cycle.
Study NCT00336791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: FAC and FEC Chemotherapy:~500 mg/m\^2 IV on day 1 of 21 day cycle.
Study NCT00336791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: FAC Chemotherapy: 50 mg/m\^2 IV on day 1 over 72 hour continuous infusion or IV bolus.
Study NCT00336791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: FAC Chemotherapy: 50 mg/m\^2 IV on day 1 over 72 hour continuous infusion or IV bolus.
Study NCT00336791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 by vein (IVPB) over 1 hour every week for 12 weeks
Study NCT00336791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: FEC: 100 mg/m\^2 IV on day 1 of 21 day cycle.
Study NCT00336791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: FEC: 100 mg/m\^2 IV on day 1 of 21 day cycle.
Study NCT01267552 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non drains will be placed during operation
Description: Non drains will be placed during operation
Study NCT01267552 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed suction drainage
Description: Closed suction drainage will be placed during operation
Study NCT02334215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Study NCT02334215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
Study NCT02334215 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Description: Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
Study NCT03014037 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Unilateral Bone Marrow Procurement
Description: A total of 61cc of bone marrow will be procured under ultrasound guidance from one posterior superior iliac spine (PSIS) via 3 passes, each at least 1 cm apart, through the bone cortex. In each pass, investigators will obtain 2.3cc of BMA with a 60cc syringes.
Study NCT02548091 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Computed tomography (CT)
Study NCT02548091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed tomography (CT)
Study NCT02971449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amazon Fire Tablet
Description: A generic amazon fire tablet with pre-loaded instructional videos
Study NCT02971449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICCM Traditional Trainins
Description: Standard, Didactic VHT Training intervention as an active comparator
Study NCT04016506 — intervention group
Intervention type: OTHER
Intervention: nutritional questionnaire
Description: nutritional questionnaire is given to the patient after the injury
Study NCT00646347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional upper limb stroke rehabilitation
Description: Patient will be given a ten weeks conventional upper limb therapy. 3 sessions will be provided weekly in the first 4 weeks and 2 therapy sessions will be provided weekly in the subsequent 6 weeks. Patients will receive half an hour of conventional therapy in each session.~Patient will be taught to carry out two and half hours conventional self practice exercise daily for a period of ten weeks.
Study NCT00646347 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuro Hand Orthosis Program (NHOP)
Description: The NHO is based on a design of dynamic hand orthosis for orthopaedic patients after hand surgery. We use it to support CVA patient's wrist and finger to perform grasping to transport an object (ball) from place to place to achieve the follows;~1. NHO can assist stroke patients to experience successful hand grasping with an object and produce voluntary movement from their paralytic arm. This successful experience will positively reinforce the patient to continue to use their paralytic arm and change the patient's behavior and perception in the arm usage.~2. The NHO Program is able to engage patients to perform their exercises and activities by themselves independently with the effect of intensive therapy.~The intervention (NHOP) group will receive same treatment intensity as the control group but with a Neuro Hand Orthosis.
Study NCT03529734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 min running
Description: This was already explained in the description of arm
Study NCT03529734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local strengthening exercises
Description: This was already explained in the description of arm
Study NCT04918069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Topical capsaicin ointment
Study NCT04918069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical placebo ointment
Study NCT00859716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE393
Description: ACE393 250 micrograms as intra muscular injection at day 0 and day 21
Study NCT00859716 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine
Description: Placebo 500 micrograms Alhydrogel as intra muscular injection at day 0 and day 21
Study NCT02504957 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Photodynamic therapy using polyhematoporphyrin
Study NCT02858596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Semi-solid feed (Terumo PG soft)
Study NCT02858596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Liquid feed (Meibalance)
Study NCT01410669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Description: MI is a client-centered counseling approach developed to deliver stage-tailored intervention messages using non-confrontational, supportive communication strategies. The client is encouraged to explore the barriers and facilitating factors associated with the behavior change. The interviewer's role is to guide the conversation and avoid use of conventional directive approaches (e.g., persuasion, providing information).~In this trial, a trained motivational interviewer meets individually with patients randomized to the intervention for one-hour at baseline, followed by four MI telephone follow up contacts at 1-, 2-, and 4-months post baseline.
Study NCT02998905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOAC
Description: Apixaban or dabigatran or edoxaban or rivaroxaban at recommended dosing for stroke prevention in atrial fibrillation. The particular agent is at the discretion of the local investigator.
Study NCT02583828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide 50mg
Study NCT02583828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50mg
Study NCT02998905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid
Description: Acetylsalicylic acid 81 mg/day
Study NCT01244789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin and paclitaxel
Description: 6 courses of iv 3-weekly chemotherapy Carboplatin AUC5 Paclitaxel 175mg/m2
Study NCT01244789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: observation
Description: active observation
Study NCT03482284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Participants receive different monosaccharides for a defined number of days.
Study NCT04171180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide/formoterol
Description: apply different dosage of budesonide/formoterol in two groups and evaluate the treatment effects.
Study NCT04171180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol
Description: apply different dosage of budesonide/formoterol in two groups and evaluate the treatment effects.
Study NCT03014037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Bone Marrow Procurement
Description: 30.5cc of bone marrow will be obtained under ultrasound guidance from each posterior superior iliac spine (PSIS) with 3 passes, at least 1 cm apart, per side (10.17cc per pass) using 60cc syringes. The collection from each PSIS will be combined to yield a total of 61cc.
Study NCT03600974 — intervention group
Intervention type: DRUG
Intervention: Neuromodulators
Description: Neuromodulators for P(+) or S(+);Flupentixol and Melitracen 1# bid;
Study NCT01907880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pamidronate
Description: 90mg IV once every 4 weeks for 3 cycles
Study NCT02442622 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational therapy
Description: Occupational therapy for de Quervain's Tenosynovitis
Study NCT02442622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occupational therapy with ASTYM
Description: Occupational therapy for de Quervain's Tenosynovitis plus ASTYM
Study NCT03991416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Understanding Your Baby
Description: Research-based knowledge on the understanding and meeting of the baby's socioemotional needs is delivered to the parents systematically by public health visitors based on a manual, cue cards, and video clips at four time points from 1 to 10 months postpartum.